European Commission

This is the 2nd Edition of the Treatment Action Group and Stop TB Partnership’s 2011 report on funding trends for tuberculosis (TB) research and development (R&D) from the baseline year 2005 through 2010, the last year for which full data is available. Updates to this report include new funding figures from the Canadian Institutes for Health Research, the Global Fund to Fight AIDS, TB, and Malaria, and Company Y; as well as revised data from Pfizer and the European Commission. In total, these donors reported an additional $13.4 million in TB R&D funding for 2010.

The last decade saw a dramatic rise in resources devoted to addressing the HIV epidemic in low- and middle- income countries, contributing to significant scale up of treatment and prevention efforts. In marking the 30th year of the epidemic, UNAIDS recently reported that treatment access had increased more than 20 times and new infections fell by nearly 25% over the decade.1